Adial Pharmaceuticals CFO holds options on 307,814 shares

Q: How many shares do ADIL CFO Vassiliki Economides’ options cover?

Vassiliki Economides directly holds options covering 307,814 common shares. The exercise price is $5.76 per share, and the options expire August 19, 2036.

Q: What is the vesting schedule for Vassiliki Economides’ ADIL options?

25% vests on the first anniversary of the grant date, August 19, 2026. The remaining shares vest in 36 equal monthly installments, subject to her continuous service through each applicable vesting date.

The options vest over time, with continuous service required through each applicable vesting date.

Available on EDGAR 10/30/2026 - 08:35 PM EDT Accepted by SEC EDGAR 10/30/2026 - 08:35 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ADIAL PHARMACEUTICALS, INC. (ADIL) Chief Financial Officer Vassiliki Economides directly holds stock options covering 307,814 common shares, as reported on October 28, 2026. The options have an exercise price of $5.76 per share and expire August 19, 2036. They vest 25% on the first anniversary of the grant date (August 19, 2026), with the remaining shares vesting in 36 equal monthly installments, subject to continuous service through each applicable vesting date.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Economides Vassiliki

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Holding	Stock Option (right to buy) ^F1	--	--	--

Holdings: Stock Option (right to buy) — 307,814 contracts (Direct)

Footnotes (1)

F1. The option shall vest as to 25% on the first anniversary of the grant date (August 19, 2026), with the remaining shares vesting in a series of 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through the applicable vesting date.

Key Figures

Common shares underlying options: 307,814 shares Exercise price: $5.76 per share Expiration date: August 19, 2036 +2 more

5 metrics

Common shares underlying options 307,814 shares Direct holdings reported October 28, 2026

Exercise price $5.76 per share Stock options

Expiration date August 19, 2036 Stock options

First vesting installment 25% On the first anniversary of the grant date, August 19, 2026

Remaining vesting installments 36 equal monthly installments Subject to continuous service through each applicable vesting date

Key Terms

exercise price, vest, continuous service

3 terms

exercise price financial

"exercise price of $5.7600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The option shall vest as to 25%"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continuous service financial

"subject to the Reporting Person's continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares do ADIL CFO Vassiliki Economides’ options cover?

Vassiliki Economides directly holds options covering 307,814 common shares. The exercise price is $5.76 per share, and the options expire August 19, 2036.

What is the vesting schedule for Vassiliki Economides’ ADIL options?

25% vests on the first anniversary of the grant date, August 19, 2026. The remaining shares vest in 36 equal monthly installments, subject to her continuous service through each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Economides Vassiliki

(Last)

(First)

(Middle)

C/O AZORA THERAPEUTICS, INC.

16501 VENTURA BLVD., SUITE 400

(Street)

ENCINO

CALIFORNIA

91436

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/28/2026

3. Issuer Name and Ticker or Trading Symbol
ADIAL PHARMACEUTICALS, INC. [ ADIL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	08/19/2036	Common Stock	307,814	$5.76	D

Explanation of Responses:

1. The option shall vest as to 25% on the first anniversary of the grant date (August 19, 2026), with the remaining shares vesting in a series of 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through the applicable vesting date.

Remarks:

Exhibit 24, Power of Attorney, is attached.

	/s/ Matthew Davidson, Attorney-in-Fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR